Home > Research > Publications & Outputs > The clinical and cost effectiveness of adapted ...

Links

Text available via DOI:

View graph of relations

The clinical and cost effectiveness of adapted dialectical behaviour therapy (DBT) for bipolar mood instability in primary care (ThrIVe-B programme): A feasibility study

Research output: Contribution to journalJournal article

Published

Standard

The clinical and cost effectiveness of adapted dialectical behaviour therapy (DBT) for bipolar mood instability in primary care (ThrIVe-B programme) : A feasibility study . / Wright, K.; Dodd, A.; Warren, F.C.; Medina-Lara, A.; Taylor, R.; Jones, Steven; Owens, C.; Javaid, M.; Dunn, B.; Harvey, J.E.; Newbold, A.; Lynch, T.

In: Trials, Vol. 19, No. 1, 560, 16.10.2018.

Research output: Contribution to journalJournal article

Harvard

APA

Wright, K., Dodd, A., Warren, F. C., Medina-Lara, A., Taylor, R., Jones, S., Owens, C., Javaid, M., Dunn, B., Harvey, J. E., Newbold, A., & Lynch, T. (2018). The clinical and cost effectiveness of adapted dialectical behaviour therapy (DBT) for bipolar mood instability in primary care (ThrIVe-B programme): A feasibility study . Trials, 19(1), [560]. https://doi.org/10.1186/s13063-018-2926-7

Vancouver

Author

Wright, K. ; Dodd, A. ; Warren, F.C. ; Medina-Lara, A. ; Taylor, R. ; Jones, Steven ; Owens, C. ; Javaid, M. ; Dunn, B. ; Harvey, J.E. ; Newbold, A. ; Lynch, T. / The clinical and cost effectiveness of adapted dialectical behaviour therapy (DBT) for bipolar mood instability in primary care (ThrIVe-B programme) : A feasibility study . In: Trials. 2018 ; Vol. 19, No. 1.

Bibtex

@article{21a05b7411eb4f8e9f014b9d03d5a7cc,
title = "The clinical and cost effectiveness of adapted dialectical behaviour therapy (DBT) for bipolar mood instability in primary care (ThrIVe-B programme): A feasibility study ",
abstract = "Background: In bipolar spectrum disorder, some individuals experience ongoing, frequent fluctuations in mood outside of affective episodes. There are currently no evidence-based psychological interventions designed to address this. This feasibility study is a phase II evaluation of a dialectical behavioural therapy-informed approach (Therapy for Inter-episode mood Variability in Bipolar [ThrIVe-B]). It seeks to examine the feasibility and acceptability of a future definitive trial evaluating the clinical and cost effectiveness of the ThrIVe-B programme. Methods/design: Patients will be randomised 1:1 to either treatment as usual only (control arm) or the ThrIVe-B intervention plus treatment as usual (intervention arm). Follow-up points will be at 3, 6, 9 and 15 months after baseline, with 9 months as the primary end point for the candidate primary outcome measures. We aim to recruit 48 individuals meeting diagnostic criteria for a bipolar spectrum disorder and reporting frequent mood swings outside of acute episodes, through primary and secondary care services and self-referral. To evaluate feasibility and acceptability, we will examine recruitment and retention rates, completion rates for study measures and feedback from participants on their experience of study participation and therapy. Discussion: Proceeding to a definitive trial will be indicated if the following criteria are met: (1) trial participation does not lead to serious negative consequences for our participants; (2) any serious concerns about the acceptability and feasibility of the trial procedures can be rectified prior to a definitive trial; (3) follow-up data at 9 months are available for at least 60% of participants; (4) at least 60% of patients in the ThrIVe-B arm complete treatment. Trial registration: ISRCTN, ISRCTN54234300. Registered on 20 July 2017. {\textcopyright} 2018 The Author(s).",
keywords = "Bipolar disorder, Cyclothymic disorder, Dialectical behaviour therapy, Psychological therapy",
author = "K. Wright and A. Dodd and F.C. Warren and A. Medina-Lara and R. Taylor and Steven Jones and C. Owens and M. Javaid and B. Dunn and J.E. Harvey and A. Newbold and T. Lynch",
year = "2018",
month = oct
day = "16",
doi = "10.1186/s13063-018-2926-7",
language = "English",
volume = "19",
journal = "Trials",
issn = "1745-6215",
publisher = "BIOMED CENTRAL LTD",
number = "1",

}

RIS

TY - JOUR

T1 - The clinical and cost effectiveness of adapted dialectical behaviour therapy (DBT) for bipolar mood instability in primary care (ThrIVe-B programme)

T2 - A feasibility study

AU - Wright, K.

AU - Dodd, A.

AU - Warren, F.C.

AU - Medina-Lara, A.

AU - Taylor, R.

AU - Jones, Steven

AU - Owens, C.

AU - Javaid, M.

AU - Dunn, B.

AU - Harvey, J.E.

AU - Newbold, A.

AU - Lynch, T.

PY - 2018/10/16

Y1 - 2018/10/16

N2 - Background: In bipolar spectrum disorder, some individuals experience ongoing, frequent fluctuations in mood outside of affective episodes. There are currently no evidence-based psychological interventions designed to address this. This feasibility study is a phase II evaluation of a dialectical behavioural therapy-informed approach (Therapy for Inter-episode mood Variability in Bipolar [ThrIVe-B]). It seeks to examine the feasibility and acceptability of a future definitive trial evaluating the clinical and cost effectiveness of the ThrIVe-B programme. Methods/design: Patients will be randomised 1:1 to either treatment as usual only (control arm) or the ThrIVe-B intervention plus treatment as usual (intervention arm). Follow-up points will be at 3, 6, 9 and 15 months after baseline, with 9 months as the primary end point for the candidate primary outcome measures. We aim to recruit 48 individuals meeting diagnostic criteria for a bipolar spectrum disorder and reporting frequent mood swings outside of acute episodes, through primary and secondary care services and self-referral. To evaluate feasibility and acceptability, we will examine recruitment and retention rates, completion rates for study measures and feedback from participants on their experience of study participation and therapy. Discussion: Proceeding to a definitive trial will be indicated if the following criteria are met: (1) trial participation does not lead to serious negative consequences for our participants; (2) any serious concerns about the acceptability and feasibility of the trial procedures can be rectified prior to a definitive trial; (3) follow-up data at 9 months are available for at least 60% of participants; (4) at least 60% of patients in the ThrIVe-B arm complete treatment. Trial registration: ISRCTN, ISRCTN54234300. Registered on 20 July 2017. © 2018 The Author(s).

AB - Background: In bipolar spectrum disorder, some individuals experience ongoing, frequent fluctuations in mood outside of affective episodes. There are currently no evidence-based psychological interventions designed to address this. This feasibility study is a phase II evaluation of a dialectical behavioural therapy-informed approach (Therapy for Inter-episode mood Variability in Bipolar [ThrIVe-B]). It seeks to examine the feasibility and acceptability of a future definitive trial evaluating the clinical and cost effectiveness of the ThrIVe-B programme. Methods/design: Patients will be randomised 1:1 to either treatment as usual only (control arm) or the ThrIVe-B intervention plus treatment as usual (intervention arm). Follow-up points will be at 3, 6, 9 and 15 months after baseline, with 9 months as the primary end point for the candidate primary outcome measures. We aim to recruit 48 individuals meeting diagnostic criteria for a bipolar spectrum disorder and reporting frequent mood swings outside of acute episodes, through primary and secondary care services and self-referral. To evaluate feasibility and acceptability, we will examine recruitment and retention rates, completion rates for study measures and feedback from participants on their experience of study participation and therapy. Discussion: Proceeding to a definitive trial will be indicated if the following criteria are met: (1) trial participation does not lead to serious negative consequences for our participants; (2) any serious concerns about the acceptability and feasibility of the trial procedures can be rectified prior to a definitive trial; (3) follow-up data at 9 months are available for at least 60% of participants; (4) at least 60% of patients in the ThrIVe-B arm complete treatment. Trial registration: ISRCTN, ISRCTN54234300. Registered on 20 July 2017. © 2018 The Author(s).

KW - Bipolar disorder

KW - Cyclothymic disorder

KW - Dialectical behaviour therapy

KW - Psychological therapy

U2 - 10.1186/s13063-018-2926-7

DO - 10.1186/s13063-018-2926-7

M3 - Journal article

VL - 19

JO - Trials

JF - Trials

SN - 1745-6215

IS - 1

M1 - 560

ER -